Cite
HARVARD Citation
Pratt, G. et al. (2018). A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma. British journal of haematology. pp. 429-433. [Online].